Biotech Investment Analyst — Drug Asset & Company Assessment
Pay
$120–200/hr
Work
Remote · Part time · 15 hrs/wk · Remote — US-based or deep US-market experience
Experience
5+ years
Eligibility
No stated location restriction
Field
Finance & accounting
Skills
Disclosure: Skillora is independent of Mercor. The apply button carries our referral code, and if you are placed, Mercor pays Skillora a fee. It does not change what you are paid, our ranking does not know which listings pay us, and selection is decided by Mercor’s own vetting.
About this role
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
- Create and critique rubrics that analyze commercial drugs and drug-development programs
- Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
- Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
- Apply your assessment across the pilot's set of companies (~5–10)
Requirements
- US-based biotech / healthcare investment analyst with a specialist-fund background
- Familiarity with biotech/pharma development programs
- Able to assess a drug asset and the company behind it end-to-end
- 5+ years evaluating biotech/pharma companies or assets
Engagement Details
- Duration: Approximately 10–20 hours over a 1–2 week pilot
- Remote — US-based
Why Participate
- Help improve expert AI evaluation of drugs and drug-development programs
- Recurring engagement for strong contributors
Similar AI training jobs
Payer & Market Access Expert — Gross-to-Net & Formulary Strategy
Disease-Area Clinician — Trial Endpoints & Prescribing
Pharma Commercial Forecasting Expert — Launch Curves